SciELO - Scientific Electronic Library Online

 
vol.62 issue53T magnetic resonance spectroscopy as a powerful diagnostic modality for assessment of thyroid nodulesImpact of an inpatient multidisciplinary glucose control management program author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


Archives of Endocrinology and Metabolism

Print version ISSN 2359-3997On-line version ISSN 2359-4292

Abstract

TUZUN, Dilek et al. Is FGF-23 an early indicator of atherosclerosis and cardiac dysfunction in patients with gestational diabetes?. Arch. Endocrinol. Metab. [online]. 2018, vol.62, n.5, pp.506-513. ISSN 2359-3997.  http://dx.doi.org/10.20945/2359-3997000000070.

Objective:

Fibroblast growth factor 23 (FGF-23) is a phosphorus-regulating hormone and plays a role in the pathogenesis of myocardial hypertrophy. The aim of this study was to evaluate the association of FGF-23 levels with echocardiographic parameters and insulin resistance (IR) in patients with gestational diabetes.

Subjects and methods:

Fifty-four pregnant patients with gestational diabetes mellitus (GDM) (age, 31.12 ± 5.72 years) and 33 healthy pregnant women (age, 29.51 ± 4.92 years) were involved in the study. Fasting insulin, fasting plasma glucose (FPG), lipid profile, oral glucose tolerance test (OGTT), FGF23, echocardiographic parameters, and carotid artery intima-media thickness (CIMT) were evaluated in the two groups.

Results:

The two groups were not significantly different in age, sex, body mass index, lipid profile, or blood pressure. Insulin, homeostatic model assessment-insulin resistance (HOMA-IR), FGF-23 levels, CIMT, left ventricular (LV) mass, LV mass index and myocardial performance index (MPI) were significantly higher in the GDM group. HOMA-IR was positively correlated with FGF-23, and insulin was positively correlated with FGF-23. Additionally, FGF-23 was positively correlated with CIMT, LV mass index, and MPI.

Conclusion:

Our findings suggest that monitoring serum FGF-23 may be useful as a non-invasive indicator of subclinical atherosclerosis in patients with GDM.

Keywords : FGF-23; myocardial performance index; gestational diabetes mellitus.

        · text in English     · English ( pdf )